Prescribers have a new liquid formulation of nitisinone as an option for the treatment of children and adults with hereditary tyrosinaemia type 1.
Orfadin 4mg/ml suspension should be shaken vigorously immediately before a dose is withdrawn and administered. The liquid is administered via an oral syringe, three of which are included in each pack. Prescribers should advise patients how to administer the correct dose.
As a result of increased tyrosine levels due to nitisinone's mode of action, patients may experience eye-related adverse effects such as conjunctivitis, corneal opacity, keratitis and photophobia.
Patients taking Orfadin should be on a tyrosine- and phenylalanine- restricted diet.